SYN-AR-A

SYN-AR-A is an investigational oral homeopathic medicinal product developed by FUTRUE R&S 2 GmbH for the treatment of grass pollen-induced allergic rhinoconjunctivitis. It was evaluated in a Phase 2 randomized, double-blind, placebo-controlled clinical trial in Germany (EudraCT 2018-003844-15) to assess its efficacy and safety in alleviating seasonal allergy symptoms such as nasal congestion, sneezing, and ocular irritation. As a homeopathic complex, SYN-AR-A likely contains a combination of highly diluted botanical extracts intended to modulate the body's immune response to allergens. The 'A' designation refers to one of three specific formulations (A, B, and C) tested in the same clinical program to determine the optimal composition for symptom relief.